Company · INM
InMed Pharmaceuticals Inc.
INM is not in Nasdaq's symbol directory of securities listed on US exchanges.
In the 12 months to Nov 19, 2026: insiders bought on 23 occasions ($282K); 7 filings by holders of 5% or more; 6 company reports (Form 8-K, since May 26, 2026).
All insider filings at the SEC · Appeared in No. 55, No. 54, No. 53, No. 52, No. 51, No. 50
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- ADAR1 Capital Management, LLC bought $240K
- Vivo Opportunity, LLC bought $42K
Every trade (23)
- BUYADAR1 Capital Management, LLC bought $35K
- BUYADAR1 Capital Management, LLC bought $5
- BUYADAR1 Capital Management, LLC bought $1K
- BUYADAR1 Capital Management, LLC bought $1
- BUYADAR1 Capital Management, LLC bought $1K
- BUYADAR1 Capital Management, LLC bought $11K
- BUYADAR1 Capital Management, LLC bought $750
- BUYADAR1 Capital Management, LLC bought $3K
- BUYADAR1 Capital Management, LLC bought $4K
- BUYADAR1 Capital Management, LLC bought $7K
- BUYADAR1 Capital Management, LLC bought $24K
- BUYADAR1 Capital Management, LLC bought $11K
- BUYADAR1 Capital Management, LLC bought $22K
- BUYADAR1 Capital Management, LLC bought $11K
- BUYADAR1 Capital Management, LLC bought $70K
- BUYADAR1 Capital Management, LLC bought $37K
- BUYVivo Opportunity, LLC bought $33
- BUYVivo Opportunity, LLC bought $23K
- BUYADAR1 Capital Management, LLC bought $2K
- BUYVivo Opportunity, LLC bought $8K
- BUYVivo Opportunity, LLC bought $2K
- BUYVivo Opportunity, LLC bought $7K
- BUYVivo Opportunity, LLC bought $924
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- Squadron Master Fund LP 0%
- Deep Track Capital, LP 5.64%
- Commodore Capital LP 5.6%
- Fairmount Funds Management LLC 19.99%
- ADAR1 Capital Management, LLC 17.2%
- Ikarian Capital, LLC 4.2%
- Vivo Opportunity Fund Holdings, L.P. 21.7%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Entry into a material definitive agreement; Completion of acquisition or disposition of assets; Results of operations and financial condition; Unregistered sales of equity securities; Material modification to rights of security holders; Change in control; Departure or appointment of directors or officers; Amendments to articles or bylaws; change in fiscal year; Amendments to or waiver of the code of ethics; Change in shell company status Nov 10, 2026
- Regulation FD disclosure Nov 9, 2026
- Amendments to articles or bylaws; change in fiscal year; Submission of matters to a vote of security holders; Other events Nov 5, 2026
- Regulation FD disclosure Nov 5, 2026
- Regulation FD disclosure Nov 3, 2026
- Notice of delisting or failure to meet a listing standard; Other events Sep 18, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.